Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) traded up 4.1% during trading on Thursday . The company traded as high as $13.55 and last traded at $13.48, with a volume of 153,470 shares traded. The stock had previously closed at $12.95.

A number of equities research analysts recently commented on the company. Mizuho boosted their target price on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the stock a “neutral” rating in a research report on Thursday, April 28th. Noble Financial assumed coverage on Adamas Pharmaceuticals in a research report on Friday, June 17th. They issued a “buy” rating and a $25.00 target price on the stock. Credit Suisse Group AG reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 22nd. JMP Securities reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, June 15th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $44.00 target price on shares of Adamas Pharmaceuticals in a research report on Tuesday, June 14th. Two investment analysts have rated the stock with a sell rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $32.00.

The firm has a 50 day moving average of $14.99 and a 200 day moving average of $15.57. The company’s market cap is $294.95 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.11. Equities analysts predict that Adamas Pharmaceuticals Inc. will post ($3.18) EPS for the current fiscal year.

An institutional investor recently raised its position in Adamas Pharmaceuticals stock. Russell Frank Co raised its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 119.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 83,773 shares of the specialty pharmaceutical company’s stock after buying an additional 45,652 shares during the period. Russell Frank Co owned 0.45% of Adamas Pharmaceuticals worth $2,395,000 at the end of the most recent quarter.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.